Listed at National Stock Exchange
Ready to commercialize lyophilized products early 2017
SAKAR HEALTHCARE LTD. has taken the final leap to get listed on NSE Emerge on this 14th October 2016. Mr. Sanjay Shah, Founder & Managing Director of the Company inaugurates listing and trading operations which unfolds the opportunity to bid basis investment rationale. The strategic plan as he shares is primarily to expand overseas operations, registering brands and introducing techo-rich products incorporating lyophilizer in the manufacturing unit. The key drivers for growth shall be the focus in marketing operations and key customer management, which has helped SAKAR to grow in leaps and bounds over the past decade.
The listing ceremony held at NSE, Mumbai was attended by Mr. Ravi Varanasi, Chief of Business Development, NSE, Mr. Aarsh Shah, Joint Managing Director-SAKAR, Mrs. Rita Shah, Director-SAKAR, Mr. Mahavir Lunawat, MD-Pantomath
Capital Advisors Pvt Ltd, along with well recognized individuals from the organization and National Stock Exchange. With ringing of the bell, SAKAR enters into the NSE Emerge platform, a moment witnessed and captured well for motivating
moving ahead. The prior roadshows at various locations of the country and the press release also helped recognize SAKAR
Healthcare Ltd. with immense confidence and credibility. The result being the process started with a positive tone and on growth curve.
SAKAR offers a basket of pharmaceutical products covering formulations:
- Oral liquid
- Cephalosporin: tablet, capsule, dry syrup, sachet
- Cephalosporin dry power injection
- Small volume parenteral-SVP
(ampoules & vials)
With the manufacturing units approved by WHO-GMP and Ministry of Health of various overseas countries, SAKAR surges
ahead with the uniqueness in the Indian Pharmaceutical industry. The enriched technology of lyophilization has been proven to deliver better quality products, having commercially viable shelf life with stable formulations. With the inclusion of lyophilizer to commercialize lyophilized products from early 2017, SAKAR has aligned further with the industry advancements meeting the expectations of partners. The giant leap to get into the NSE platform and planned introduction of lyophilized products early 2017 have definitely brightens the vision of SAKAR HEALTHCARE LTD.